3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
toripalimab
4
pembrolizumab
4
Gemcitabine
4
tislelizumab
2
durvalumab
2
Nivolumab
2
Cisplatin
2
Carboplatin
2
AZD4547
2
tipifarnib
1
tesetaxel
1
sapanisertib
1
regorafenib
1
pyrotinib
1
nintedanib
1
famitinib
1
disitamab vedotin
1
camrelizumab
1
bintrafusp alfa protein, human
1
atezolizumab
1
anlotinib
1
aldesleukin
1
advexin
1
Vitamin B 12
1
Trastuzumab
1
Taxes
1
Surgical Procedures, Operative
1
Saline Solution
1
Resistance Training
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Transitional Cell
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled